Finance

Lists
TAKP34:BVMF
Takeda Pharmaceutical Co Ltd BDR
R$115.68
0.00%
(0.00) 1D
Nov 6, 4:56:00 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for TAKP34...
Open
R$115.68
High
R$115.68
Low
R$115.68
Mkt. cap
69.10B
Avg. vol.
24.00
Volume
2.00
52-wk high
R$118.90
52-wk low
R$73.15
Shares outstanding
1.60B
No. of employees
47K
Open
R$115.68
High
R$115.68
Low
R$115.68
Mkt. cap
69.10B
Avg. vol.
24.00
Volume
2.00
52-wk high
R$118.90
52-wk low
R$73.15
Shares outstanding
1.60B
No. of employees
47K
News stories
From web sources and news partners
Profile
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. In 2026, Julie Kim was noted in a news item as "CEO-elect". Wikipedia
About Takeda Pharmaceutical Co Ltd BDR
CEOChristophe Weber | Christophe Weber
Employees47K
FoundedJun 12, 1781
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websitetakeda.com
Last report
Oct 29, 2026
Fiscal period
Q2 2027
- / -
Revenue / Est. (JPY)
1.19T / 1.16T
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
1.19T
1.09T
1.22T
1.19T
Cost of goods sold
401.15B
453.33B
406.68B
392.09B
Cost of revenue
401.15B
453.33B
406.68B
392.09B
Research and development expenses
175.23B
187.96B
167.40B
171.23B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
282.78B
291.96B
286.51B
271.71B
Operating expense
661.30B
519.65B
612.60B
503.56B
Total operating expenses
1.06T
972.98B
1.02T
895.65B
Operating income
129.25B
121.56B
200.62B
291.45B
Other non operating income
-197.22B
181.53B
-3.54B
-50.69B
EBT including unusual items
133.86B
-455.02B
162.72B
155.97B
EBT excluding unusual items
114.17B
71.49B
161.92B
242.09B
Income tax expense
30.13B
-86.62B
49.46B
-36.49B
Effective tax rate
22.51%
19.04%
30.40%
-23.40%
Other operating expenses
67.13B
-64.27B
53.17B
-21.52B
Net income
103.64B
-368.47B
113.20B
192.43B
Net profit margin
8.70%
-33.66%
9.28%
16.21%
Earnings per share
-
-
-
-
Interest and investment income
181.35B
-
-
39.18B
Interest expense
-
-239.63B
-35.70B
-37.30B
Net interest expenses
181.35B
-239.63B
-35.70B
1.88B
Depreciation and amortization charges
-
-
-
-
EBITDA
319.89B
192.73B
363.66B
455.88B
Gain or loss from assets sale
358.00M
1.46B
-6.00B
8.84B
Upcoming events
AI content may include mistakes. Learn more
Google apps